SHANGHAI, May 6, 2020 /PRNewswire/ -- 111, Inc. ("111" or
the "Company") (Nasdaq: YI), a leading integrated online and
offline healthcare platform in China, today announced that Mr. Anfeng
Guo ("Mr. Guo"), a former Vice President of Oncology Business Unit
at Bristol Myers Squibb, is appointed as Chief Innovation Officer
of 111, effective May 1st,
2020.
In his new position, Mr. Guo will oversee operation and
innovation of internet medical platform across the Company. He will
also manage Hanhong Pharmaceutical Co., Ltd., a wholly owned
subsidiary of 111, to further pursue the endeavors of the Company
in the commercialization of innovative drugs, especially cancer
drugs and relevant consumables and equipment.
Dr. Yu Gang, Co-Founder and
Executive Chairman of 111, said, "The omni-channel
commercialization platform strategy ("omni-channel strategy") of
111 has been helping numerous pharmaceutical companies to
commercialize their innovative drugs across China. I am very pleased to see Anfeng embrace
this new important challenge when our omni-channel strategy is at
the critical development stage. His appointment will further
accelerate the development of the Company. With his years of
international experience and extensive network, Anfeng has
developed a remarkable knowledge in the areas of drug
commercialization, especially cancer drugs. I am confident that
under his leadership, our team will further expand our capability
to build innovative services with development of more innovative
drugs for the benefits of patients."
Mr. Guo commented on his appointment, "I am attracted to 111 by
the extensive experiences, innovative ideas and great minds of the
two founders Dr. Yu Gang and Mr. Liu
Junling. As China further deepen
reforms in healthcare with the issuance of 4+7 volume-based
procurement policy and launch of many innovative drugs as well as
in response to the outbreak of COVID-19, the internet is ushering a
new age of medicine. I am confident in the future development of
internet medicine and healthcare. Leveraging on the power of
internet medicine and the strength of 111's e-commerce
capabilities, our plan is to create an efficient and powerful drug
commercialization team with strong executive capabilities and to
build an expert-led internet medical platform for innovative drugs
to empower doctors and patients."
Biography of Mr. Anfeng Guo
Mr. Anfeng Guo is a veteran in China's pharmaceutical market for over twenty
years and worked in renowned multinational pharmaceuticals
including Pfizer, Bayer, AstraZeneca and Bristol Myers Squibb,
across various fields such as sales, marketing, ecological chain
construction, etc. Prior to joining 111, he was the Vice President
of both Oncology Business Unit and Virology Business Unit at
Bristol Myers Squibb, creating China's first excellent immuno-oncology sales
team. Under his leadership, the Virology Business Unit at Bristol
Myers Squibb realized a V-shaped reversal with dominant share in
the immune-oncology market.
Mr. Guo graduated from Nanjing Tech University in 2000 and
received his bachelor's degree in bio-pharmaceuticals. He received
his EMBA degree in international healthcare from Nanjing University in 2018.
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading
integrated online and offline healthcare platform in China. The Company provides hundreds of
millions of consumers with better access to pharmaceutical products
and healthcare services directly through its online retail pharmacy
and indirectly through its offline pharmacy network. 111 also
offers online healthcare services through its internet hospital, 1
Clinic, which provides consumers with cost-effective and convenient
online consultation and electronic prescription services. In
addition to providing direct services to consumers through its
online retail pharmacy, 111 also enables offline pharmacies to
better serve their customers. The Company's online wholesale
pharmacy, 1 Drug Mall, serves as a one-stop shop for pharmacies to
source a vast selection of pharmaceutical products. The Company's
new retail platform, by integrating the front and back ends of the
pharmaceutical supply chain, has formed a smart supply chain, which
transforms the flow of pharmaceutical products to pharmacies and
modernizes how they serve their customers.
For more information on 111, please
visit http://ir.111.com.cn/.
For more information, please contact:
111, Inc.
Media Relations
Email: press@111.com.cn
Phone: +86-021-2053 6666 (China)
111, Inc.
Investor Relations
Email: ir@111.com.cn
GCM Strategic Communications
IR Counsel
Email: 111.ir@gcm.international
View original
content:http://www.prnewswire.com/news-releases/mr-anfeng-guo-a-former-bms-oncology-business-unit-vice-president-joins-111-inc-as-chief-innovation-officer-301053765.html
SOURCE 111, Inc.